Lexicon Pharmaceuticals
LXRX
$1.58
Share price
2.60%
Change (1 day)
-33.89%
Change (1 year)
Categories
P/S ratio for Lexicon Pharmaceuticals (LXRX)
P/S ratio as of April 2024 (TTM): 323
According to Lexicon Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 322.867. At the end of 2023 the company had a P/S ratio of 311.
P/S ratio history for Lexicon Pharmaceuticals from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 311 | -88.01% |
| 2022 | > 1000 | 31.73% |
| 2021 | > 1000 | 9661.37% |
| 2020 | 20.2 | 1372.78% |
| 2019 | 1.37 | -87.63% |
| 2018 | 11.1 | -4.13% |
| 2017 | 11.5 | -33.11% |
| 2016 | 17.3 | 62.75% |
| 2015 | 10.6 | -63.22% |
| 2014 | 28.8 | -93.06% |
| 2013 | 416 | -60.01% |
| 2012 | > 1000 | 341.36% |
| 2011 | 236 | 137.98% |
| 2010 | 99.0 | 254.62% |
| 2009 | 27.9 | 371.12% |
| 2008 | 5.93 | -28.35% |
| 2007 | 8.27 | 114.35% |
| 2006 | 3.86 | 23.92% |
| 2005 | 3.11 | -60.96% |
| 2004 | 7.97 | -7.68% |
| 2003 | 8.64 | 22.76% |
| 2002 | 7.04 | 258.18% |
| 2001 | 1.96 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Thermo Fisher Scientific TMO | 5.11 | -98.42% | 🇺🇸 USA |
 Illumina ILMN | 4.32 | -98.66% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | 7.39 | -97.71% | 🇺🇸 USA |
 Ultragenyx RARE | 8.39 | -97.40% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | 9.52 | -97.05% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | 3.09 | -99.04% | 🇺🇸 USA |
 Aerie Pharmaceuticals AERI | 3.52 | -98.91% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 6.35 | -98.03% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | 142 | -55.89% | 🇺🇸 USA |